Johnson & Johnson (NYSE:JNJ) Shares Sold by Pictet & Cie Europe SA

Pictet & Cie Europe SA trimmed its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 30.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 212,034 shares of the company’s stock after selling 93,008 shares during the period. Johnson & Johnson comprises approximately 1.4% of Pictet & Cie Europe SA’s holdings, making the stock its 21st largest holding. Pictet & Cie Europe SA’s holdings in Johnson & Johnson were worth $37,579,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $26,000. Steward Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $38,000. Advocacy Wealth Management Services LLC raised its position in shares of Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.6 %

NYSE:JNJ opened at $171.79 on Friday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock has a market cap of $451.67 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. The business has a fifty day moving average of $175.41 and a 200-day moving average of $174.52. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.48 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on JNJ shares. Citigroup lowered their price objective on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Wells Fargo & Company upped their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Raymond James upped their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.